European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1] RINVOQ met all primary and secondary endpoints, demonstrating rapid a... Biopharmaceuticals, Dermatology, Regulatory AbbVie, RINVOQ, upadacitinib, atopic dermatitis, JAK inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news